Stockreport

Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Rapport Therapeutics, Inc.  (RAPP) 
PDF Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling pati [Read more]